Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADPT 
Adaptive Biotechnologies Corp (ADPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ADPT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14
1 Year Target Price $14
| 3 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.17% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.92B USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 8 | Beta 1.94 | 52 Weeks Range 3.98 - 13.68 | Updated Date 09/14/2025 |
52 Weeks Range 3.98 - 13.68 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -59.07% | Operating Margin (TTM) -42.52% |
Management Effectiveness
Return on Assets (TTM) -14% | Return on Equity (TTM) -57.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1806671068 | Price to Sales(TTM) 9.36 |
Enterprise Value 1806671068 | Price to Sales(TTM) 9.36 | ||
Enterprise Value to Revenue 8.8 | Enterprise Value to EBITDA -1 | Shares Outstanding 152274000 | Shares Floating 117369688 |
Shares Outstanding 152274000 | Shares Floating 117369688 | ||
Percent Insiders 2.34 | Percent Institutions 97.89 |
Upturn AI SWOT
Adaptive Biotechnologies Corp
Company Overview
History and Background
Adaptive Biotechnologies was founded in 2009. It focuses on leveraging the adaptive immune system to develop clinical products for diagnosing and treating diseases. Its key milestones include developing clonoSEQ for minimal residual disease monitoring and partnering with Microsoft to map the adaptive immune system.
Core Business Areas
- Minimal Residual Disease (MRD): clonoSEQ is used to detect and monitor minimal residual disease in patients with lymphoid cancers, providing insights into treatment response and recurrence risk.
- Immune Medicine: Utilizing the immune system to diagnose and treat diseases. Focuses on T-cell and B-cell receptor sequencing to identify and understand disease signatures.
- Drug Discovery: Identifying drug targets by screening the adaptive immune system for potential biomarkers and therapeutic agents.
Leadership and Structure
Adaptive Biotechnologies is led by a CEO (typically reporting to a Board of Directors). The company has departments for Research and Development, Commercial Operations, and Corporate Functions.
Top Products and Market Share
Key Offerings
- clonoSEQ: clonoSEQ is a commercial assay used for minimal residual disease (MRD) monitoring in blood cancers like multiple myeloma and acute lymphoblastic leukemia. While exact market share data is difficult to determine, clonoSEQ is a leading product in its niche. Competitors include Invivoscribe, Asuragen, and various lab-developed tests (LDTs).
- T-Detect: T-Detect is a diagnostic test that leverages the adaptive immune system to detect various diseases, including COVID-19. The market share is still evolving as the product continues to gain traction. Competitors include Quanterix, Thermo Fisher Scientific and Roche.
Market Dynamics
Industry Overview
The industry involves immune-driven diagnostics and therapeutics, witnessing growing interest due to advances in sequencing technologies and personalized medicine.
Positioning
Adaptive Biotechnologies is positioned as a leader in applying immunosequencing to diagnostics and drug discovery, with strong partnerships and proprietary technology.
Total Addressable Market (TAM)
The TAM for immunosequencing in diagnostics and drug discovery is estimated to be in the billions of dollars. Adaptive Biotechnologies is positioned to capture a significant portion of this market through its clonoSEQ and T-Detect products, as well as its drug discovery partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary immunosequencing technology
- Established clonoSEQ product with clinical utility
- Partnerships with leading pharmaceutical companies
- Strong intellectual property portfolio
Weaknesses
- High operating expenses
- Reliance on key partnerships
- Limited profitability to date
- Susceptibility to reimbursement changes
Opportunities
- Expanding clonoSEQ applications to new cancers
- Developing new immune-based diagnostic tests
- Advancing drug discovery programs through partnerships
- Growing adoption of personalized medicine
Threats
- Competition from established diagnostic companies
- Regulatory hurdles for new diagnostic tests
- Changes in reimbursement policies
- Potential for technological obsolescence
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- DGX
Competitive Landscape
Adaptive Biotechnologies' competitive advantage lies in its proprietary immunosequencing technology and established clonoSEQ product. However, it faces competition from larger, more established diagnostic companies.
Major Acquisitions
AstraZeneca Collaboration (Not an acquisition but a significant deal)
- Year: 2020
- Acquisition Price (USD millions):
- Strategic Rationale: To leverage Adaptive's immune profiling platform to discover and develop novel therapeutics for cancer.
Growth Trajectory and Initiatives
Historical Growth: Adaptive Biotechnologies' growth has been driven by increasing adoption of clonoSEQ and the development of new diagnostic tests.
Future Projections: Future growth projections would depend on analyst estimates, which consider factors such as market trends, competitive landscape, and the company's strategic initiatives.
Recent Initiatives: Recent initiatives include expanding clonoSEQ's applications, developing new diagnostic tests, and advancing drug discovery programs.
Summary
Adaptive Biotechnologies is positioned as a leader in immunosequencing, particularly with its clonoSEQ product. While it faces challenges with profitability, the company's innovative technology, strategic partnerships, and expanding market opportunities create a promising outlook. Investors should closely monitor the company's progress in achieving profitability and managing competition. Key risks include reimbursement policies and competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adaptive Biotechnologies Corp
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Chairman Mr. Chad M. Robins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 619 | Website https://www.adaptivebiotech.com |
Full time employees 619 | Website https://www.adaptivebiotech.com | ||
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.